FierceBiotech Jan 7, 2026 Fierce Biotech Fundraising Tracker '26: Soley sees $200M series C; Rakuten rakes in $100M
FierceBiotech Jan 7, 2026 GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push
FierceBiotech Jan 6, 2026 Arrowhead takes aim at obesity market with early data on dual gene silencing assets
FierceBiotech Jan 6, 2026 In Structure licensing deal, Roche commits $100M to shore up GLP-1 position
FierceBiotech Jan 6, 2026 Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs
FierceBiotech Jan 6, 2026 Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator
FierceBiotech Jan 6, 2026 Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact
FierceBiotech Jan 6, 2026 FDA cites severe liver injury risk, unclear benefit behind Sanofi's MS drug rejection
FierceBiotech Jan 6, 2026 UK biotech eyes $1B deal to enable eye gene therapy to be delivered in doctors' offices
FierceBiotech Jan 5, 2026 Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
FierceBiotech Jan 5, 2026 Abbott launches AI-based Libre Assist, its new in-app feature for meal planning